PTX-022 topical gel 3.9% (sirolimus)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for PTX-022 topical gel 3.9% (sirolimus), covering 2026-03-27 to 2026-03-27. Get the full timeline:
Most recent: Clinical Trial Update: A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Cutaneous Venous Malformations [Phase 2]